dc.creator | Gurwith, Marc | |
dc.creator | Condit, Richard C. | |
dc.creator | Excler, Jean-Louis | |
dc.creator | Robertson, James S. | |
dc.creator | Kim, Denny | |
dc.creator | Fast, Patricia E. | |
dc.creator | Drew, Stephen | |
dc.creator | Wood, David | |
dc.creator | Klug, Bettina | |
dc.creator | Whelan, Mike | |
dc.creator | Moore, Tamala Mallett | |
dc.creator | Khuri-Bulos, Najwa | |
dc.creator | Smith, Emily R. | |
dc.creator | Chen, Robert T | |
dc.creator | Kochhar, Sonali | |
dc.date.accessioned | 2020-10-19T19:40:07Z | |
dc.date.available | 2020-10-19T19:40:07Z | |
dc.date.created | 2020 | |
dc.identifier.issn | 0264-410X | spa |
dc.identifier.other | https://doi.org/10.1016/j.vaccine.2020.09.042 | spa |
dc.identifier.uri | http://hdl.handle.net/20.500.12010/14589 | |
dc.description.abstract | Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral
vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of
such vaccines. The standardized and structured assessment provided by the template would also help to
contribute to improved communication and support public acceptance of licensed live-attenuated viral
vaccines. | spa |
dc.format.extent | 6 páginas | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | spa |
dc.publisher | Vaccine | spa |
dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
dc.subject | Brighton Collaboration | spa |
dc.subject | CEPI | spa |
dc.subject | COVID-19 | spa |
dc.subject | Vaccine | spa |
dc.subject | Benefit-risk | spa |
dc.subject | Safety | spa |
dc.subject | Live | spa |
dc.subject | Attenuated | spa |
dc.subject | Viral | spa |
dc.subject | Template | spa |
dc.title | Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines | spa |
dc.type.local | Artículo | spa |
dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
dc.subject.lemb | COVID-19 | spa |
dc.subject.lemb | SARS-CoV-2 | spa |
dc.subject.lemb | Coronavirus | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
dc.rights.local | Abierto (Texto Completo) | spa |
dc.identifier.doi | https://doi.org/10.1016/j.vaccine.2020.09.042 | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |